Mike Davis previously worked as clinical team leader at the FDA’s Division of Psychiatry before serving as chief medical ...

Robert F. Kennedy Jr. testified in front of largely combative congresspeople on vaccine policy, his MAHA report and more; the ...

In the latest installment of his column, Kaye/Bassman's Michael Pietrack shares five ways leaders can help their teams after ...

Eli Lilly's bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, ...

Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean ...

Isaralgagene civaparvovec is a “potential best-in-class gene therapy for Fabry disease,” according to analysts at H.C.

With much to cover, Democrats tackled Kennedy’s MAHA report; the firing of all members of the CDC’s ACIP committee; and much ...

Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new ...

In addition to cutting most of its staff, including two C-suite executives, Leap Therapeutics is winding down research and ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Drug pricing, budget cuts, tariffs and other shifts under the Trump administration undermine the biopharma and healthcare ...

Curay, who stepped into the role as the agency’s top drug regulator in January, is departing in July, according to an email ...